SEC Form 4 · accession 0000899243-18-017372
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara K Finck
Officer — Chief Medical Officer
Period of report
Jun 18, 2018
Accepted (ET)
Jun 20, 2018 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | Jun 18, 2018 | M | 1,760 | $1.42 | A | 38,803 | D | |
| Common Stock, $0.0001 par valueF1 | Jun 18, 2018 | S | 1,760 | $15.00 | D | 37,043 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.42 | Jun 18, 2018 | M | 1,760 | D | — | Nov 21, 2023 | Common Stock | 1,760 | 88,221 | D |
Explanation of responses
- F1Includes 2,707 shares acquired on May 15, 2018 pursuant to Issuer's employee stock purchase plan.
- F2The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- F3A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from July 30, 2013, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.